Life Sciences Seminar: Bad to the Bone (Marrow): Macrophages in Leukemia
Life Science Seminar
Bad to the Bone (Marrow): Macrophages in Leukemia
Dr. Benjamin Frisch
Assistant Professor of Pathology
University of Rochester School of Medicine and Dentistry
Abstract:
Acute myelogenous leukemia (AML) is the most common acute leukemia in adults, and accounts for approximately 15% of pediatric leukemias. A diagnosis of AML has devastating consequences and, in adults, a 5-year survival rate of less than 30 percent. Treatment options for AML are limited, and the majority of patients are treated with strategies initially developed in the 1970s. Therefore, there is a critical need for the development of new therapeutic targets. In solid cancers, such as breast and prostate cancer, macrophages are known to play an important role in tumor development and progression. However, comparatively little is known about the role of macrophages in hematologic malignancies such as AML. To gain a better understanding of mechanisms of disease progression, research in our lab has focused on interactions between AML and the bone marrow microenvironment including the involvement of macrophages. Through this research we have discovered an important intersection between leukemic cellular metabolism, macrophage dysfunction, and bone marrow microenvironmental damage. This mechanistic pathway leads to increased leukemic progression, and may prove to be a promising new target in AML therapy.
Intended Audience:
All are Welcome!
To request an interpreter, please visit myaccess.rit.edu
Event Snapshot
When and Where
Who
This is an RIT Only Event
Interpreter Requested?
No